Publication Name	World Journal of Diabetes
Manuscript ID	3175
Country	United Kingdom

Received	2013-04-12 07:58
Peer-Review Started	2013-04-12 11:36
To Make the First Decision	2013-05-14 18:48
Return for Revision	2013-05-20 09:51
Revised	2013-06-03 22:36
Second Decision	2013-06-19 12:58
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-06-20 01:06
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-07-31 15:25
Publish the Manuscript Online	2013-08-15 11:51

ISSN	1948-9358 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Minireviews
Article Title	Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors
Manuscript Source	Invited Manuscript
All Author List	Cecil Stanley Thompson
Funding Agency and Grant Number
Corresponding Author	Cecil Stanley Thompson, PhD, Department of Surgery, Division of Surgery and Interventional Science, University College London Medical School, Royal Free Campus, Pond Street, London NW3 2QG, United Kingdom. cecil.thompson@nhs.net
Key Words	Diabetic nephropathy; Phosphodiesterase type 5; Glomerular filtration rate; Inflammation; Angiotensin Ⅱ
Core Tip	Diabetic nephropathy a leading cause of end-stage renal disease, is characterized by dysfunctional metabolic, haemodynamic and inflammatory pathways leading to glomerular hypertension. These pathways were normalized following treatment with phosphodiesterase type 5 inhibitors, which initiated renal vascular smooth muscle relaxation. This therapeutic option for treating diabetic nephropathy may negate the need for costly renal dialysis or transplantation.
Publish Date	2013-08-15 11:51
Citation	Thompson CS. Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors. World J Diabetes 2013; 4(4): 124-129
URL	http://www.wjgnet.com/1948-9358/full/v4/i4/124.htm
DOI	http://dx.doi.org/10.4239/wjd.v4.i4.124

Full Article (PDF)	WJD-4-124.pdf
Manuscript File	3175-Review.doc
Answering Reviewers	3175-Peer review(s).pdf
Copyright License Agreement	3175-Copyright assignment.pdf
Peer-review Report	3175-Peer review(s).pdf
Scientific Editor Work List	3175-Scientific editor work list.doc